The rEP and BLM groups presented a slight reduction in tumor oxygenation, which was assessed at 17.3% and 22.8%, respectively (rEP pretreatment: 79.9 ± 1.7%; rEP posttreatment: 66.1 ± 6.6%; BLM pretreatment: 77.3 ± 3.0%; and BLM posttreatment: 59.7 ± 3.8%). The gene discussed is BLM; the disease is neoplasm.